Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: The FATIMA study

Heart

Volumn 80, Issue 1, 1998, Pages 35-39

  Chamuleau, S A J ^a   De Winter, R J ^a,b   Levi, M ^b   Adams, R ^a   Buller H R ^b   Prins, M H ^b   Lie, K I ^a   Peters, R J G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Acute myocardial infarction; FATIMA study; Low molecular weight heparin; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID CALCIUM; ALTEPLASE; NADROPARIN;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG EFFECT; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HEPARINIZATION; HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031825704     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.80.1.35     Document Type: Article

References (35)

1. Fuster V. Coronary thrombolysis - a perspective for the practicing physician. N Engl J Med 1993;329:723 -5.
2. Fibrinolytic Therapy Trialists' (FFT) collaborative group. Indications tor Fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311 -22.
3. ISIS 2 (second international study of infarct survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17-187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988;ii: 346 -60.
4. Granger CE, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Results from the GUSTO-I trial. Circulation 1996;93:870 -8.
5. Gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65 -71.
6. The SCATI (Studio sulla calciparina nell'angina e nella trombosi ventricolare nell'infarcto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989;ii:182 -6.
7. Ridker PM, Herbert PR, Fuster V, et al. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993;341:1574 -7.
8. Wood AJJ. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847 -59.
9. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-17.
10. Arnout J, Simoons ML, de Bono D, et al. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992;20:513 -19.
11. De Bono DP, Simoons ML, Thijssen J, et al. Effect of early intravenous heparin on coronary patency infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European cooperative study group trial. Br Heart J 1992;67:122 -8.
12. Hsia J, Hamilton WP, Kleiman N, et al, for the HART Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-7.
13. Prins MH, Hirsh J. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991;67:3-11A.
14. ISIS 3 (Third international study of infarct survival) Collaborative Group. ISIS 3: a randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753 -69.
15. Kroon C, ten Hove WR, de Boer A, et al. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 1992;86: 1370-5.
16. Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987;48:591 -6.
17. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation 1994;89:1449 -68.
18. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The TASMAN Study Group. N Engl J Med 1996; 334:682-7.
19. Ten Cate JW, Koopman MM, Prins MH, et al. Treatment of venous thromboembolism. Thromb Haemost 1995;74:197 -203.
20. FRISC (Fragmin during instability in coronary artery disease) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347: 561 -8.
21. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease (Fragmin in unstable coronary artery disease study (FRIC)). Circulation 1997; 96:61 -8.
22. The Thrombolysis in Myocardial Infarction (TIMI) IIA Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI IIA. J Am Coll Cardiol 1997;29:1474-82.
23. Strandberg LE, Kahan T, Lundin P, et al. Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study. Haemostasis 1996,26:247 -57.
24. The GUSTO-investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673 -82.
25. Prandoni P, Lensing AW, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441 -5.
26. Klootwijk P, Cobbaert C, Fioretti P, et al. Noninvasive assessment of reperfusion and reocclusion after thrombolysis in acute myocardial infarction. Am J Cardiol 1993;72: 75 -84G.
27. Hohnloser SH, Zabel M, Kasper W, et al. Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers. J Am Coll Cardiol 1991;18:44 -9.
28. Ten Cate H, Lamping RJ, Henny ChP, et al. Automated amidolytic method for determining heparin, a heparinoid and a low molecular weight heparin fragment based on their anti-Xa activity. Clin Chem 1984;30:860 -4.
29. Tew CJ, Lane DA, Thompson E, et al. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222. Br J Haematol 1988;70:335 -40.
30. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl Med 1985;312: 932 -6.
31. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142 -54.
32. The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615 -22.
33. Neuhaus KL, van Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomised r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994;90:1638-42.
34. Amman EM, for the TIMI 9A investigators. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624 -30.
35. The global use of strategies to open occluded coronary arteries (GUSTO) IIa investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631 -7.